|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Xq22 deletions that encompass PLP1 (Xq22-PLP1-DEL) are notable for variable expressivity of neurological disease traits in females ranging from a mild late-onset form of spastic paraplegia type 2 (MIM# 312920), sometimes associated with skewed X-inactivation, to an early-onset neurological disease trait (EONDT) of severe developmental delay, intellectual disability, and behavioral abnormalities.
|
31448840 |
2020 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results were confirmed by immunohistochemistry; both myelin (proteolipid protein, P = 0.03) and neurofilaments (SMI-312, P = 0.02) were lower in ALS.
|
31002412 |
2019 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
The possible cross-talk between the PLP enzymes hSR and hCBS (human cystathionine β-synthase) is discussed, as the former produces D-serine and the latter produces H<sub>2</sub>S, both of which stimulate the NMDAR and both of which have been implicated in neuronal infarction pursuant to ischemic stroke.
|
30918891 |
2019 |
|
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Tau deposits were often associated with slight myelin disruption and the presence of small PLP1-immunoreactive globules and dots in the ipsilateral corpus callosum 6 months after inoculation of sarkosyl-insoluble fractions from every tauopathy.
|
31191295 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Experimental studies on several microarray and RNA-Seq datasets demonstrate that the proposed SLDSF is more effective than several representative characteristic gene selection methods (e.g., RGNMF, GNMF, RPCA and PMD) for selecting cancer characteristic genes.
|
29844511 |
2018 |
|
Epilepsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Further exploration of these roles has revealed a functional interaction of PipX with PipY, a pyridoxal-phosphate (PLP) protein involved in PLP homeostasis whose mutations in the human ortholog cause epilepsy.
|
30483512 |
2018 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast to oligodendrocytes, MeCP2 does not bind to promoter region of MBP and PLP in C6 glioma suggest that MeCP2 differentially regulates the gene expression in different cell types.
|
29992497 |
2018 |
|
Leishmaniasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Various other product (putrescine) based analogs and transition state or PLP (cofactor) based analogs are being synthesized against diseases such as Leishmaniasis, Malaria and others discussed in the article.
|
28971766 |
2018 |
|
Malaria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Various other product (putrescine) based analogs and transition state or PLP (cofactor) based analogs are being synthesized against diseases such as Leishmaniasis, Malaria and others discussed in the article.
|
28971766 |
2018 |
|
Neuralgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Such an understanding will improve amputees' quality of life by blocking the mechanisms that trigger and/or maintain PLP and chronic neuropathic pain.
|
28921418 |
2018 |
|
Toxoplasmosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immuno-efficacy of DNA vaccines encoding PLP1 and ROP18 against experimental Toxoplasma gondii infection in mice.
|
29626423 |
2018 |
|
brain cyst
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the immunized mice exhibited longer survival times (44.7 ± 2.1 days for ROP18/PLP1 and 47.2 ± 2.9 days for ROP18/PLP1 + IL-18) and lower brain cyst burden (68.9% for ROP18/PLP1 and 72.4% for ROP18/PLP1 + IL-18) than control mice after T. gondii challenge.
|
29626423 |
2018 |
|
Striatonigral Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, transgenic PLP-α-syn mice show a distinctive oligodendroglial α-synucleinopathy that is associated with progressive striatonigral degeneration linked to abnormal neuroinflammatory response.
|
29298733 |
2018 |
|
Hereditary pyropoikilocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ALP = alkaline phosphatase; HPP = hypophosphatasia; PEA = phosphorethanolamine; PLP = pyridoxal-5-phosphate; PPi = inorganic pyrophosphate; TNSALP/TNAP = tissue-nonspecific alkaline phosphatase.
|
30289311 |
2018 |
|
Progressive Neoplastic Disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
One-year response was determined using RECIST for CT and EORTC criteria for PET, coded as complete response (CR or CMR), partial response (PR or PMR), stable disease (SD or SMD) or progressive disease (PD or PMD).
|
30137228 |
2018 |
|
Mitochondrial Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A review of PubMed publications was performed from the past 12 months that identified 16 new PMD genes and/or pathogenic variants, and recognition of expanded phenotypes for a wide variety of mitochondrial disease genes.
|
30199403 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Experimental studies on several microarray and RNA-Seq datasets demonstrate that the proposed SLDSF is more effective than several representative characteristic gene selection methods (e.g., RGNMF, GNMF, RPCA and PMD) for selecting cancer characteristic genes.
|
29844511 |
2018 |
|
Progressive cGVHD
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One-year response was determined using RECIST for CT and EORTC criteria for PET, coded as complete response (CR or CMR), partial response (PR or PMR), stable disease (SD or SMD) or progressive disease (PD or PMD).
|
30137228 |
2018 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We further corroborated the structure of the corresponding gene causal networks using datasets generated from the brain of mice with ablation of key network drivers, such as UGT8, CNP and PLP1, which were identified from human AD brain data.
|
29110684 |
2017 |
|
Autoimmune Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In order to gain mechanistic insights into multiple sclerosis (MS) pathogenesis, we utilized a multi-dimensional approach to test the hypothesis that mutations in myelin proteins lead to immune activation and central nervous system autoimmunity in MS. Mass spectrometry-based proteomic analysis of human MS brain lesions revealed seven unique mutations of PLP1; a key myelin protein that is known to be destroyed in MS.
|
28191734 |
2017 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that colitis promotes rapid enteric neurogenesis in adult mice and humans through differentiation of Sox2- and PLP1-expressing cells, which represent enteric glia and/or neural progenitors.
|
28566702 |
2017 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Confocal laser scanning microscopy indicated that the targeting molecule FA promotes PLP-<sup>131</sup>I uptake by melanoma B16F10 cells, which was further confirmed by the cell incorporation rate via <sup>131</sup>I activity detection as measured by a gamma counter.
|
28532129 |
2017 |
|
Leukoencephalopathy
|
0.010 |
Biomarker
|
group |
BEFREE |
The proteolipid protein 1 gene (PLP1) is located on chromosome Xq22.2 and is related to X-linked recessive leukoencephalopathy (Pelizaeus-Merzbacher disease: PMD).
|
28328133 |
2017 |
|
Pendular Nystagmus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pendular nystagmus (PN) has been reported in some subtypes of HSP caused by PLP1 (SPG2) or paraplegin (SPG7) mutation.
|
29246608 |
2017 |
|
Hepatic Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that SPECT and perforin-like protein 1 (PLP1) are critical for transcellular migration by P. falciparum sporozoites and demonstrates the importance of cell traversal for liver infection by this human pathogen.
|
28355563 |
2017 |